妇科癌症患者盆腔毒性肠道微生物组:与对照组的比较及直肠臭氧治疗的效果。(MicrOzoGineTox) (MicrOGineTox)
女性妇科肿瘤及放疗和化疗继发盆腔毒性患者的肠道微生物组特征:与对照组的比较及直肠臭氧治疗的效果
Patients treated for gynecological tumors with radiotherapy (RT) and/or chemotherapy (CT) frequently develop pelvic toxicity (TPIRQT), a condition that can become persistent, progressive, and refractory to standard treatments. This toxicity, affecting the rectum (proctitis), bladder (cystitis), and vagina (mucositis), severely deteriorates quality of life. Standard options for refractory cases are limited; at our center, rectal ozone therapy is used with high rates of symptomatic improvement (66-75%). Emerging evidence suggests a link between gut microbiota and the development of TPIRQT. However, it is unknown how rectal ozone therapy may influence the gut microbiome or if this modulation is part of its therapeutic mechanism. This prospective observational study will investigate the potential relationship between gut microbiome profiles (composition and diversity), the presence and severity of TPIRQT, and the response to rectal ozone therapy.
研究概览
详细说明
Patients treated for gynecological tumors with radiotherapy (RT) and/or chemotherapy (CT) frequently develop pelvic toxicity (TPIRQT), a condition that can become persistent, progressive, and refractory to standard treatments. This toxicity, affecting the rectum (proctitis), bladder (cystitis), and vagina (mucositis), severely deteriorates quality of life. Standard options for refractory cases are limited; at our center, rectal ozone therapy is used with high rates of symptomatic improvement (66-75%). Emerging evidence suggests a link between gut microbiota and the development of TPIRQT. However, it is unknown how rectal ozone therapy may influence the gut microbiome or if this modulation is part of its therapeutic mechanism. This prospective observational study will investigate the potential relationship between gut microbiome profiles (composition and diversity), the presence and severity of TPIRQT, and the response to rectal ozone therapy.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Bernardino Clavo, MD, PhD
- 电话号码:34928449278
- 邮箱:bernardinoclavo@gmail.com
研究联系人备份
- 姓名:Francisco Rodríguez-Esparragón, BSc, PhD
- 电话号码:34928449288
- 邮箱:afrodesp@gmail.com
学习地点
-
-
Las Palmas
-
Las Palmas de Gran Canaria、Las Palmas、西班牙、35019
- 招聘中
- Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC)
-
接触:
- Bernardino Clavo, MD, PhD
- 电话号码:34928449278
- 邮箱:bernardinoclavo@gmail.com
-
接触:
- Francisco Rodríguez-Esparragón, BSc, PhD
- 电话号码:34928449288
- 邮箱:afrodesp@gmail.com
-
-
Tenerife
-
San Cristóbal de La Laguna、Tenerife、西班牙、38296
- 招聘中
- Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias - Universidad de La Laguna
-
接触:
- Jacob Lorenzo-Morales, Prof
- 电话号码:34922318402
- 邮箱:jmlorenz@ull.edu.es
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Patients with gynecological tumors treated with RT and/or CT with or without chronic pelvic toxicity (TPIRQT).
描述
Inclusion Criteria for all patients (Cases and Controls):
-
Adult women (>=18 years).
-
Diagnosed with gynecological tumors (any location and stage).
-
Previously treated with radiotherapy and/or chemotherapy.
-
Must accept and sign the specific informed consent for this study.
Additional Inclusion Criteria for inclusion in the TPIRQT Group (Cases):
-
Must present chronic TPIRQT with >= 3 months of duration after habitual symptomatic treatment.
-
Must have a toxicity Grade of 2 (moderate symptoms, limiting instrumental ADL) or higher, according to the CTCAE v.5.0 scale.
Exclusion Criteria for all patients (Cases and Controls):
- Not meeting all inclusion criteria.
- Presence of active inflammatory bowel disease (e.g., Crohn's Disease, Ulcerative Colitis) or a history of major gastrointestinal resection (excluding appendectomy) that could significantly alter gut anatomy and microbiota.
- Any uncontrolled intercurrent illness or psychiatric condition that, in the investigator's opinion, would limit compliance with study requirements or interfere with the interpretation of results.
- Unwillingness or inability to provide written informed consent for study participation.
学习计划
研究是如何设计的?
设计细节
- 观测模型:CASE_CONTROL
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
|---|
|
TPIRQT Group (Cases)
Patients with gynecological tumors treated with RT and/or CT who develop chronic pelvic toxicity (TPIRQT) and are referred for compassionate-use rectal ozone therapy at the Chronic Pain Unit. Samples and data will be collected before and after ozone therapy |
|
Control Group
pelvic toxicity (TPIRQT). This group will be matched by age (± 5 years) and primary tumor location. Samples and data will be collected once during a follow-up visit. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Comparison of gut microbiome profile (composition and diversity) between TPIRQT and Control groups
大体时间:Baseline (single time point for controls, pre-ozone for cases)
|
Gut microbiome composition and diversity (from a single sample) in control patients will be compared to the baseline profile of patients with TPIRQT. |
Baseline (single time point for controls, pre-ozone for cases)
|
|
Change in gut microbiome profile (composition and diversity) in patients with TPIRQT after rectal ozone therapy.
大体时间:Baseline (pre-ozone therapy) , 4 Months (post-ozone therapy)
|
Gut microbiome composition and diversity will be analyzed from stool samples using 16S ribosomal RNA gene sequencing. |
Baseline (pre-ozone therapy) , 4 Months (post-ozone therapy)
|
|
Correlation of gut microbiome profile with grade of pelvic toxicity.
大体时间:Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).
|
Toxicity will be assessed using: i) the CTCAE v.5.0 scale from the NCI , and ii) the EORTC QLQ-CX24 questionnaire. This will be evaluated for its relationship to microbiome data. |
Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Correlation of gut microbiome profile with health-related quality of life (HRQoL).
大体时间:Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).
|
HRQoL will be assessed using: i) the EQ-5D-5L questionnaire, and ii) the EORTC QLQ-C30 questionnaire. This will be evaluated for its relationship to microbiome data. |
Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).
|
|
Correlation of gut microbiome profile with anxiety and depression levels.
大体时间:Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).
|
Anxiety and depression will be assessed using the Hospital Anxiety and Depression Scale (HADS). This will be evaluated for its relationship to microbiome data. |
Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).
|
|
Correlation of gut microbiome profile with biochemical markers of oxidative stress and inflammation.
大体时间:Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).
|
Serum samples will be collected to analyze biochemical parameters of oxidative stress and inflammation and their potential relationship with gut microbiome composition. |
Baseline (for Control group); Baseline, 4 Months (for TPIRQT group).
|
合作者和调查者
合作者
调查人员
- 学习椅:Bernardino Clavo, MD, PhD、Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC), Las Palmas, Spain
- 首席研究员:Francisco Rodríguez-Esparragón, BSc, PhD、Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC), Las Palmas, Spain
- 首席研究员:Jacob Lorenzo-Morales, Prof、Instituto Universitario de Enfermedades Tropicales y Salud Publica de Canarias, Universidad La Laguna
出版物和有用的链接
一般刊物
- Wang A, Ling Z, Yang Z, Kiela PR, Wang T, Wang C, Cao L, Geng F, Shen M, Ran X, Su Y, Cheng T, Wang J. Gut microbial dysbiosis may predict diarrhea and fatigue in patients undergoing pelvic cancer radiotherapy: a pilot study. PLoS One. 2015 May 8;10(5):e0126312. doi: 10.1371/journal.pone.0126312. eCollection 2015.
- Wang L, Wang X, Zhang G, Ma Y, Zhang Q, Li Z, Ran J, Hou X, Geng Y, Yang Z, Feng S, Li C, Zhao X. The impact of pelvic radiotherapy on the gut microbiome and its role in radiation-induced diarrhoea: a systematic review. Radiat Oncol. 2021 Sep 25;16(1):187. doi: 10.1186/s13014-021-01899-y.
- Clavo B, Navarro M, Federico M, Borrelli E, Jorge IJ, Ribeiro I, Rodriguez-Melcon JI, Carames MA, Santana-Rodriguez N, Rodriguez-Esparragon F. Long-Term Results with Adjuvant Ozone Therapy in the Management of Chronic Pelvic Pain Secondary to Cancer Treatment. Pain Med. 2021 Sep 8;22(9):2138-2141. doi: 10.1093/pm/pnaa459. No abstract available.
- Clavo B, Navarro M, Federico M, Borrelli E, Jorge IJ, Ribeiro I, Rodriguez-Melcon JI, Carames MA, Santana-Rodriguez N, Rodriguez-Esparragon F. Ozone Therapy in Refractory Pelvic Pain Syndromes Secondary to Cancer Treatment: A New Approach Warranting Exploration. J Palliat Med. 2021 Jan;24(1):97-102. doi: 10.1089/jpm.2019.0597. Epub 2020 May 5.
- Clavo B, Ceballos D, Gutierrez D, Rovira G, Suarez G, Lopez L, Pinar B, Cabezon A, Morales V, Oliva E, Fiuza D, Santana-Rodriguez N. Long-term control of refractory hemorrhagic radiation proctitis with ozone therapy. J Pain Symptom Manage. 2013 Jul;46(1):106-12. doi: 10.1016/j.jpainsymman.2012.06.017. Epub 2012 Oct 26.
- Clavo B, Canovas-Molina A, Ramallo-Farina Y, Federico M, Rodriguez-Abreu D, Galvan S, Ribeiro I, Marques da Silva SC, Navarro M, Gonzalez-Beltran D, Diaz-Garrido JA, Cazorla-Rivero S, Rodriguez-Esparragon F, Serrano-Aguilar P. Effects of Ozone Treatment on Health-Related Quality of Life and Toxicity Induced by Radiotherapy and Chemotherapy in Symptomatic Cancer Survivors. Int J Environ Res Public Health. 2023 Jan 13;20(2):1479. doi: 10.3390/ijerph20021479.
- Clavo B, Santana-Rodriguez N, Llontop P, Gutierrez D, Ceballos D, Mendez C, Rovira G, Suarez G, Rey-Baltar D, Garcia-Cabrera L, Martinez-Sanchez G, Fiuza D. Ozone Therapy in the Management of Persistent Radiation-Induced Rectal Bleeding in Prostate Cancer Patients. Evid Based Complement Alternat Med. 2015;2015:480369. doi: 10.1155/2015/480369. Epub 2015 Aug 18.
- Li L, Yang Z, Yi Y, Song Y, Zhang W. Gut microbiota and radiation-induced injury: mechanistic insights and microbial therapies. Gut Microbes. 2025 Dec;17(1):2528429. doi: 10.1080/19490976.2025.2528429. Epub 2025 Jul 6.
- Ma CY, Zhao J, Xu XT, He XL, Qin SB, Zhou JY. Predictive biomarkers in the gut microbiome and metabolome for severe acute radiation enteritis in cervical cancer radiotherapy. Discov Oncol. 2025 Jul 1;16(1):1220. doi: 10.1007/s12672-025-03077-y.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 2025-436-1
- PIFIISC25/52 (其他赠款/资助编号:FIISC (Fundación Canaria Inst. Investig. Sanitaria Canarias))
- CIGC'25/26 (其他赠款/资助编号:Cabildo de Gran Canaria (CIGC))
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
- It will be available (after request): Individual participant data (IPD) that underlie the results reported in further articles, after deidentification
- Data will be available after publication, ending 36 months following article publication.
- They will be available for investigators whose proposed use of the data has been apd by an independent review committee identified for this purpose.
IPD 共享时间框架
Data will be available after publication, ending 36 months following article publication.
IPD 共享访问标准
They will be available for investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.